© Eppendorf AG 2019Eppendorf’s strategic changes are paying off: Positive first half-year 2019

August 2019. Global Eppendorf Group charted a strong first half-year in 2019 with a significant surge in Group sales to €378.5m ($419.6m; £346m) which corresponds to an organic increase in sales of 12.8% (same period 2018: €335.6m) or +8.8% in local currencies. All of the company’s market regions contributed to growth, but sales have been particularly outstanding in China (+ ca. 20%) and North America (+15%). Due to extensive investments income from operations (EBIT) slightly declined by €0.4m (prior period 2018: €67.3m) amounting to an EBIT margin of 17.6% (prior year: 20.0%).

As part of the targeted implementation of its company strategy, Eppendorf is continuing to heavily invest in new product and service solutions as well as in digitalization and new business models. This includes expansion of production capacity and infrastructure at its German sites at Hamburg, Oldenburg/Holstein, Leipzig and Jülich as well as in the United States at Enfield, CT. Construction projects represent important efforts in the company’s push for further profitable and sustainable growth. In view of these investments and assuming comparable exchange rates for 2019, the company assumes that EBIT in 2019 will remain at or around the prior-year level of €153.7 million.

Thomas Bachmann, President & CEO of Eppendorf AG explained positive half-years results with an overall favourable market environment, and the extraordinary commitment of Eppendorf’s employees worldwide which includes handling company change in addition.

Source: Eppendorf AG 

Back to section

Other Articles Recommended

B2Bioworld offers you background information

Future Lab Work: Designing and Testing Environments
Sascha Beutel, Professor of Chemistry and seasoned research manager at Institut für Technische Chemie (TCI) on do’s and don’t’s in re-configuring infrastructures, conceptual thinking, shrewd tech combinations, and savvy partnering

Big Data & Research – Acquisition, Analytics, and Exploitation
Ulrich M Gassner, Professor of Public Law at Universität Augsburg, Germany and Founder-director of the university’s Centre for E-Health Law. Discussing inter alia issues in healthcare, DigiMed Bavaria, the reach of GDPR

Disclaimer: You agree that B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from B2Bioworld sites. Links to third-party sites are for your convenience only. Their inclusion on B2Bioworld's sites does not imply any endorsement, guarantee, warranty or representation by B2Bioworld.